Pacific Edge (ASX:PEB) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:PEB Pacific Edge Ltd ASX:PEB
40 GF Score
Price A$0.24
GF Value A$0.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Pacific Edge 5-Year Yield-on-Cost %?

Pacific Edge ASX:PEB 40 5-Year Yield-on-Cost % is 0.00 as of Jul. 15, 2026. GuruFocus rates ASX:PEB with a GF Score™ of 40/100 and a GF Value™ of A$0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 64 Medical Diagnostics & Research companies, Pacific Edge ranks worse than 1562498.44% on this metric.

Pacific Edge's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Pacific Edge's 5-Year Yield-on-Cost % or its related term are showing as below:



ASX:PEB's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.455
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Pacific Edge  (ASX:PEB) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Pacific Edge 5-Year Yield-on-Cost % Related Terms


ASX:PEB vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison

For the Diagnostics & Research subindustry, Pacific Edge's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacific Edge 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Pacific Edge's 5-Year Yield-on-Cost % falls into.


ASX:PEB
40GF Score
Pacific Edge Ltd ASX:PEB
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacific Edge 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Pacific Edge is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Pacific Edge (ASX:PEB) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 15, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pacific Edge and its competitors. According to the industry distribution chart, Pacific Edge ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry.
Is Pacific Edge's 5-Year Yield-on-Cost % too high?
Pacific Edge's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Pacific Edge ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Pacific Edge has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pacific Edge ranks #999999 out of 64 companies for 5-Year Yield-on-Cost %. This places Pacific Edge in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.46, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pacific Edge and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Edge's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.24 — trading 380% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Pacific Edge's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Edge (ASX:PEB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued. The current stock price of A$0.24 is trading 380% above its estimated GF Value™ of A$0.05. GuruFocus considers Pacific Edge to be Significantly Overvalued.

Key valuation signals for ASX:PEB:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: A$0.05 vs. price of A$0.24 (380% above fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacific Edge Business Description

Address 87 Saint David Street, P.O. Box 56, Dunedin, STL, NZL, 9016
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
40GF Score

Get the complete analysis for ASX:PEB

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.24
Price
A$0.05
GF Value